Russia will seek authorisation from SA’s medicines regulator for its single-shot Sputnik Light coronavirus vaccine after a study showed it is 70% effective at preventing transmission of the Delta variant three months after inoculation.

Sputnik Light is the first component of the two-shot Sputnik V vaccine, developed by the Gamaleya National Research Centre of Epidemiology and Microbiology with backing from the Russian Direct Investment Fund (RDIF). It has been authorised as a stand-alone vaccine in more than 15 countries, while Sputnik V has been approved in 70 countries...

Subscribe now to unlock this article.

Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).

There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.

Cancel anytime.

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.